Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

News
Anti-CD20 Monoclonal Antibody Shows Favorable Benefit for Relapsing Multiple Sclerosis
03/31/2022
The first fully human anti-CD20 monoclonal antibody, ofatumumab, provided a favorable benefit-risk profile in patients with relapsing multiple sclerosis.
The first fully human anti-CD20 monoclonal antibody, ofatumumab, provided a favorable benefit-risk profile in patients with relapsing multiple sclerosis.
The first fully human anti-CD20...
03/31/2022
Neurology
News
FDA Approves Evoke Spinal Cord Stimulation System for Chronic Intractable Pain
03/25/2022
The US Food & Drug Administration recently approved the Evoke® Spinal Cord Stimulation (SCS) System for the treatment of chronic intractable pain of the trunk and/or limbs.
The US Food & Drug Administration recently approved the Evoke® Spinal Cord Stimulation (SCS) System for the treatment of chronic intractable pain of the trunk and/or limbs.
The US Food & Drug...
03/25/2022
Neurology

Advertisement

News
Concussion Associated With Heightened Risk of Subsequent Mental Health Issues in Youth
03/25/2022
Children and teenagers who sustain a concussion are at increased risk of mental health issues, psychiatric hospitalization, and self-harm, suggest new study findings.
Children and teenagers who sustain a concussion are at increased risk of mental health issues, psychiatric hospitalization, and self-harm, suggest new study findings.
Children and teenagers who...
03/25/2022
Neurology
News
Pandemic Increased Mortality Among Older Adults With Alzheimer Disease
03/23/2022
The early phase of the COVID-19 pandemic was associated with excess mortality in older adults with Alzheimer disease and related dementias (ADRD) in the United States—particularly among those who identified as Asian, Black, or Hispanic.
The early phase of the COVID-19 pandemic was associated with excess mortality in older adults with Alzheimer disease and related dementias (ADRD) in the United States—particularly among those who identified as Asian, Black, or Hispanic.
The early phase of the COVID-19...
03/23/2022
Neurology
News
Physical Activity Program Improves Employee Mental Health in Less Than 2 Months
03/21/2022
Recent study finds workplace physical activity program reported feeling less anxious, stressed, and depressed, and said they felt more alert during the day and slept better at night.
Recent study finds workplace physical activity program reported feeling less anxious, stressed, and depressed, and said they felt more alert during the day and slept better at night.
Recent study finds workplace...
03/21/2022
Psych Congress Network

Advertisement

News
Updated DSM-5 Text Revision Officially Released
03/21/2022
The revised DSM-5-TR includes updates and clarifying modifications to the criteria sets for more than 70 disorders, updates to the descriptive text, and also examines the impact of racism and discrimination.
The revised DSM-5-TR includes updates and clarifying modifications to the criteria sets for more than 70 disorders, updates to the descriptive text, and also examines the impact of racism and discrimination.
The revised DSM-5-TR includes...
03/21/2022
Psych Congress Network
News
FDA Approves Donepezil Transdermal Patch for Alzheimer Disease
03/21/2022
The US Food and Drug Administration has approved Adlarity® (donepezil transdermal system) for release in the fall of 2022. Adlarity is indicated in the treatment of adults with Alzeheimer-type mild to severe dementia symptoms. Adlarity is...
The US Food and Drug Administration has approved Adlarity® (donepezil transdermal system) for release in the fall of 2022. Adlarity is indicated in the treatment of adults with Alzeheimer-type mild to severe dementia symptoms. Adlarity is...
The US Food and Drug...
03/21/2022
Psych Congress Network
News
FDA Sets Date to Review Pimavanserin, an Alzheimer Disease Psychosis Therapy
03/17/2022
The FDA plans to review the resubmitted supplemental New Drug Application for pimavanserin, a drug used for the treatment of hallucinations and delusions associated with Alzheimer disease psychosis.
The FDA plans to review the resubmitted supplemental New Drug Application for pimavanserin, a drug used for the treatment of hallucinations and delusions associated with Alzheimer disease psychosis.
The FDA plans to review the...
03/17/2022
Neurology

Advertisement

News
Deep Learning Algorithm Identifies Differences in Brains of Boys and Girls with Autism
03/15/2022
Functional brain organization differs between boys with autism and girls with autism, according to a deep learning study out of the Stanford University School of Medicine in California.
Functional brain organization differs between boys with autism and girls with autism, according to a deep learning study out of the Stanford University School of Medicine in California.
Functional brain organization...
03/15/2022
Psych Congress Network
News
Migraine Linked With Potential Pregnancy Risks
03/10/2022
Women with migraine who are pregnant have an increased risk of preterm delivery, gestational high blood pressure, and preeclampsia, suggest study findings.
Women with migraine who are pregnant have an increased risk of preterm delivery, gestational high blood pressure, and preeclampsia, suggest study findings.
Women with migraine who are...
03/10/2022
Neurology

Advertisement

Advertisement

News

Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Gene therapy
News
Concerns Linger After Gene Therapy Shows Long-Term Benefit for Cerebral Adrenoleukodystrophy
10/28/2024
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel...
10/28/2024
Neurology
Patient with family
News
During Recovery, Stroke Patients Benefit from Supportive Social Networks
10/24/2024
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and...
10/24/2024
Neurology
International Stroke Burden Saw Hike Over Last 30 Years
News
International Stroke Burden Saw Hike Over Last 30 Years
10/22/2024
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has...
10/22/2024
Neurology
Hands holding a head in profile with an illustrated heart over brain
News
Antiseizure Meds May Increase Cardiovascular Risk in Older Adults With Epilepsy
10/21/2024
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy...
10/21/2024
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
Investigational Drug Improves Motor Function in Patients With SMA
News
Investigational Drug Improves Motor Function in Patients With SMA
10/16/2024
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational...
10/16/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use